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Executive Summary 
INTRODUCTION 
The progesterone vaginal ring (PVR) is a ring-shaped device used by women in the postpartum period to extend 
the contraceptive effectiveness of lactational amenorrhea. The ring is inserted in the vagina 6–9 weeks 
postpartum (for study purposes; 30–90 days in normal service delivery conditions) for continuous use for up to 
3 months and replaced with a new ring if breastfeeding is continued and extended contraception is desired. The 
ring diffuses a continuous flow of low-dose progesterone through the vaginal walls, which enters the 
bloodstream and regulates the woman’s fertility by suppressing ovulation. Previous studies showed that 
contraceptive vaginal rings are safe, effective, and well accepted in varied cultural settings. However, the extent 
to which the ring is acceptable in the sub-Saharan African context is unknown, especially since vaginal rings are 
a new technology and use of vaginal products such as tampons is limited in the region. 
STUDY OBJECTIVES 
This study examined the acceptability of the PVR in Nigeria as part of a larger project that was also conducted in 
Kenya and Senegal. The specific objectives of the study were to assess the factors influencing the acceptability 
of the method among clients, their partners, providers, community members, and those who were counseled 
but did not choose the method, to inform future introduction efforts. 
METHODS 
The study involved follow-up of participants who chose the ring, interviews with providers at baseline and 
endline, as well as cross-sectional interviews with women who were counseled on but did not choose the ring 
(PVR nonusers) and key stakeholders. A total of 58 women were enrolled for follow-up, another 5 were enrolled 
for in-depth interviews, and 58 PVR nonusers were interviewed upon exit. Women were enrolled for up to 6 
months or 2 ring cycles. Data collection involved completion of case record forms (CRFs) by providers during 
enrollment; quantitative exit interviews with clients during enrollment, at 3 months and at 6 months following 
ring use or at discontinuation; quantitative exit interviews with PVR nonusers; in-depth interviews with a subset 
of PVR users at 1 month, 3 months, and 6 months following ring use; in-depth interviews with spouses of PVR 
users at endline; focus group discussions with community leaders at endline; and self-administered interviews 
with providers at baseline and endline. Analysis of the quantitative data entailed simple frequencies. Directed 
content analysis techniques were employed for analyzing the qualitative data. 
KEY FINDINGS 
 Acceptability of the ring: The majority of participants who completed the two ring cycles indicated 
that they would use the ring in the future (92%), their partners or family members would support 
future use (95%), they would recommend or had already recommended the ring to their friends or 
family members (100% and 86%, respectively), and that they were willing to pay for the method 
(71%).  
 Reasons for choosing the ring: The most commonly cited reason among those who chose the PVR 
was that the method was provided free of charge (47%). The second and third reasons were that 
the method was user-controlled (36%) and perceived to have fewer side effects (35%). Most 
participants also found the ring easy to insert, remove, and reinsert. 
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 Client profile: Among the women who chose the PVR, 47% were between the ages of 20 and 29, 
had at least secondary level education (45%), and resided in urban or peri-urban areas (98%). In 
addition, all the women who participated in the study were married (100%) and 50% wanted to 
space the next birth by at least two years.  
 Prior use of family planning: The majority of the women were first-time contraceptive users (62%). 
Among women who had previously used a method, the methods ever used were: pills (7%), 
injectables (10%), implants (9%), emergency contraceptive pills (2%), male condoms (7%), and 
intrauterine contraceptive devices (IUDs) (3%). 
 Discontinuation of use: Participants who discontinued use of the ring did so for various reasons 
including experiencing side effects, personal discomfort, misconception about the method, and 
experiencing an adverse event.    
IMPLICATIONS 
 Findings from the study indicate that women and their partners, as well as family planning service 
providers, have positive attitudes toward the PVR, which is vital to its acceptance within the larger 
society. 
 Findings from the study also suggest that the PVR could be a value-adding innovation for birth 
spacing in Nigeria. This is supported by the fact that the age distribution of participants and the 
proportion of first-time users of contraception among them coincided with the age groups and 
category of women where unmet need for family planning services is the highest. 
 Eighty-one percent of participants chose to continue using the PVR for up to 6 months compared 
with the national average rate of contraceptive continuation in Nigeria of 50%, suggesting high 
acceptance of the PVR that could contribute to an increased contraceptive prevalence rate (CPR) 
in the country. National government, donor agencies, and implementing partners should pay 
special attention to meeting the contraceptive needs of women during the postpartum period in 
their overall strategies of improving maternal and child health. 
 Rights-based approaches might prove beneficial for the uptake of this new technology since 
findings from this study indicate that 30% of users chose the PVR solely because it is user-
initiated and controlled, which could insinuate a high value on autonomy. 
 Concerted efforts to educate the community and family planning providers across the country are 
essential prior to the registration and introduction of the PVR. To this end, the Population Council 
has commenced engagement with Civil Society Organizations (CSOs) across the country for the 
sole purpose of reaching various levels of government, community stakeholders, and women’s 
groups to ensure that anticipated obstacles are managed in a timely manner. Continuous 
engagement must be emphasized in order to place the ring within a rights-based framework, 
dispel misconceptions, and address concerns of potential users and providers. 
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Introduction 
The progesterone vaginal ring (PVR) is used to extend the contraceptive effectiveness of lactational 
amenorrhea among breastfeeding women. The ring is inserted in the vagina 6–9 weeks postpartum (for 
study purposes; 30–90 days in normal service delivery conditions) for continuous use for up to 3 months 
and replaced with a new ring if breastfeeding is continued and extended contraception is desired. Women 
can use four rings successively for up to one year postpartum. The PVR functions by diffusing a continuous 
flow of progesterone through the vaginal walls—approximately 10 mg per day—which then enters the 
bloodstream and regulates the woman’s fertility by suppressing ovulation. Progesterone also thickens the 
cervical mucus, thereby inhibiting sperm penetration into the uterus. Clinical trials showed that PVR is an 
effective contraceptive method (Sivin et al. 1997; Massai et al. 1999). The method was first registered in 
Chile and Peru in 1998 for use by postpartum women but has since been expanded to other Latin 
American countries, including Bolivia, the Dominican Republic, Ecuador, and Guatemala (Reproductive 
Health Supplies Coalition [RHSC] 2011).   
Previous studies conducted by the Population Council have demonstrated that vaginal rings are well 
accepted in settings as culturally diverse as Australia, Egypt, Latin America, Singapore, and the United 
States (RHSC 2011). However, the extent to which PVR is acceptable in the sub-Saharan African context is 
unknown, especially since vaginal rings are a new technology in this setting and use of vaginal products 
such as tampons is limited in the region. An understanding of the acceptability of the ring is important for 
informing the introduction of the method in the region. Sub-Saharan Africa in particular presents an 
opportunity for expanding the use of the method given relatively long breastfeeding durations; high unmet 
need for contraception, especially during the postpartum period; and the potential for multiple channels of 
introducing the method to potential users, including public and private clinics as well as private 
pharmacies and community distribution systems (Haggerty and Rutstein 1999; Bradley et al. 2012). 
Moreover, since the use of PVR is predicated upon women breastfeeding at least four times a day, it 
provides an opportunity to promote breastfeeding while ensuring contraceptive protection, thereby 
benefiting both mothers and their infants. 
To understand the extent of acceptability of the method, the Population Council conducted acceptability 
studies in Kenya, Nigeria, and Senegal. This report presents findings from the study in Nigeria. The study 
was one component of a number of activities, including global and national consultations with key 
stakeholders, assessments and documentation of the regulatory and procurement frameworks, and 
market segmentation and demand analysis aimed at informing the introduction of the method in the 
country. 
STUDY OBJECTIVES 
This study examined the acceptability of PVR in Nigeria as part of a larger project that was also conducted in 
Kenya and Senegal. The specific objective of the study was to assess the factors influencing the acceptability of 
the method among clients, their partners, providers, community members, and women who were counseled on 
but did not choose the method. 
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STUDY CONTEXT  
Nigeria, the most populous country in Africa, has a population of more than 173 million with a rate of natural 
increase of 2.8% (PRB 2012); however, the country lags behind in most health indices. Rates of maternal and 
child mortality, after showing a slight decline in the past years, are now rising, and currently stand at 
576/100,000 and 128/1,000 respectively, and the total fertility rate (TFR) is 5.5 (NDHS 2013). Currently, the 
unmet need for contraception in the postpartum period is 65% as opposed to 16% for regular use (NDHS 
2013). Furthermore, while the total need for modern contraception among postpartum women between 9 and 
12 months is approximately 80%, the actual met need is only 15%, resulting in an unmet need of 65% (Borda et 
al. 2010). Although 67% of women of reproductive age would prefer to space their pregnancies by two or more 
years, up to 23% of births occur within 24 months (NDHS 2013). This indicates a strong need to increase the 
accessibility of contraceptive options that would serve the needs of women in the postpartum period. 
 
According to the 2013 NDHS, breastfeeding in Nigeria is very prominent with 97% breastfeeding prevalence; 
however, only 13% of all infants were exclusively breastfed from birth up to the age of 6 months. The median 
duration for any breastfeeding was 18.3 months, while the median duration for exclusive breastfeeding was 
less than 1 month (NDHS 2013).  
 
Despite sound policy and programmatic interventions to increase uptake of contraceptives in Nigeria over the 
last two decades, the contraceptive prevalence rate (CPR) for modern methods is currently 10%, which has not 
improved significantly from 3.5% in 1999 (NDHS 2013) and remains one of the lowest in sub-Saharan Africa 
(SSA). Following the renewed global commitments culminating in the 2012 London Summit on Family 
Planning—which promised to reach an additional 120 million new users of quality modern contraceptives—the 
Federal Ministry of Health (FMoH) in collaboration with reproductive health stakeholders in Nigeria has set an 
ambitious new target of raising the CPR from 10% to 36% by 2018. As part of the effort to achieve this 
objective, meeting the contraceptive need of women in the immediate postpartum period and beyond is an 
integral component of the renewed commitment. Consequently, greater emphasis must be placed on making 
contraceptives that are proven effective for postpartum use, such as the PVR, and are easily accessible and 
available.  
 
Based on recent trends in current use of family planning methods, the PVR has the potential to be an effective 
family planning method for women in the postpartum period. Understanding the extent of acceptability of the 
PVR will be crucial in determining how best this contraceptive technology would be placed within the existing 
health systems framework in sub-Saharan Africa.  
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Methods 
During this study, both quantitative and qualitative data were collected from the women who participated 
(users) and their partners, healthcare providers who enrolled and monitored the users, women who opted 
not to use the ring (nonusers), and key community stakeholders.   
STUDY DESIGN 
A total of 97 women were screened across the two sites; of those, 58 were eligible and recruited to 
participate in the study. Potential study participants were counseled on all contraceptive options appropriate 
for use during the postpartum period when referred for family planning services. Women who chose the PVR 
were instructed that the use of the ring entailed enrollment in a study and were given detailed information 
about the ring so that their consent to participate in the study was well informed. 
  
Women were eligible to participate in the study if they could provide informed consent, met all the inclusion 
criteria, and did not meet any of the exclusion criteria. Inclusion and exclusion criteria can be found in 
Appendix A. 
 
Study participants were followed prospectively to measure the ring’s acceptance (continuation rate and 
satisfaction) for up to 6 months (2 ring cycles) or discontinuation. Data were collected from users by means 
of a quantitative survey questionnaire. To complement the quantitative data, qualitative data were collected 
from 5 additional women to better understand the intricacies of everyday use, through an in-depth interview 
questionnaire. Providers were also interviewed pre- and post-training and at study end using a questionnaire 
guide. Focus group discussions (FGDs) were held with other stakeholders who may have some influence on 
users’ behaviors. 
 
Once the enrollment target of 58 women was achieved, an additional 5 women were screened and recruited 
to participate in an in-depth interview (IDI). They completed a separate informed consent form and were also 
interviewed at months 1, 3, and 6.   
 
STUDY SETTING 
The study was conducted at Wuse General Hospital in Abuja and University Hospital in Ibadan. Study sites 
were selected in conjunction with the Ministries of Health (MOH) based on onsite availability of postpartum 
family planning services, affiliation with the Nigerian Urban Reproductive Health Initiative (NURHI), and 
ability to meet research standards and global Good Clinical Practice (GCP) guidelines.  
 
STUDY PROCEDURES 
The study was preceded by a mapping exercise that involved consultative meetings with key government, 
regulatory, and development agencies; social marketing organizations; research institutions; 
manufacturers/distributors of health commodities; community/advocacy groups; institutions involving 
public/private partnerships; and other organizations providing family planning services in the country. The 
purpose of the exercise was to determine the perspectives of the stakeholders regarding the method and 
the acceptability study. The next step involved obtaining the ethical, research, and regulatory approvals 
necessary for importation of rings into the country and for conducting the study. 
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Ethics Clearances 
As this study was part of a larger multicountry acceptability study, the joint study protocol was first reviewed 
and approved by the Population Council’s Institutional Review Board (IRB) in New York. Subsequently, the 
protocol was revised for further review by ethics committees in the Federal Capital Territory (FCT), Abuja, and 
University of Ibadan where the study was carried out. The local committees, FCT Health Research Ethics 
Committee and the Institute for Advanced Medical Research and Training (IAMRAT), reviewed and approved 
the protocol on December 12, 2012, and November 15, 2012, respectively. In each case, the approval was 
renewed for one additional year due to a delay in commencing the study. As a final step, the study protocol 
was reviewed, approved, and registered by the National Agency for Food and Drug Administration and 
Control (NAFDAC). 
Ring Importation 
An importation permit was granted by NAFDAC (NAFDAC/DER/CT/PVR/VOL.1) on August 14, 2013. The rings 
were imported directly from the manufacturer Grunenthal, with headquarters in Chile, to the Population 
Council office in Nigeria, which subsequently distributed the rings to the study facilities in Wuse General 
Hospital in Abuja and the University College Hospital in Ibadan. The rings were shipped in two batches. The 
first batch of 190 rings was imported and received on October 2, 2013, and the second batch of 125 rings 
was received on January 29, 2014. 
Training of Providers and Data Collectors 
Trainings sessions were coordinated and conducted with obstetricians and gynecologists, service providers, 
and nurses prior to study initiation. Four providers and 5 data collectors who were directly involved in the 
study were trained. In addition, 28 obstetricians and gynecologists selected from tertiary hospitals across 
the country were trained to serve as a pool of local trainers in the country. 
Sites Initiation and Monitoring  
Monitoring visits to each site to ascertain capacity and readiness to accommodate the study also occurred 
prior to study initiation. The sites were assessed in terms of their capacity to provide 24-hour service, a 
private space for provider/client interaction (including counseling), availability of pregnancy and HIV 
screening kits, availability of cabinets where data and research commodities could be locked, and sufficient 
client load. Subsequently, providers and monitors maintained a facility binder designed to keep track of all 
activities that occurred at the project sites. In addition, the study monitor conducted regular site visits to 
ensure compliance with study procedures, good clinical practice, ethical conduct of the study, and 
recordings of adverse and serious adverse events, if any. Participants were also instructed to report all side 
effects, including adverse or serious adverse events (AEs or SAEs), while providers were trained to ask about 
and record all side effects that women reported. 
Recruitment and Enrollment of Study Participants 
The recruitment process entailed providers counseling postpartum clients seeking family planning services 
on all available methods including PVR, so that all clients had a choice of methods. Clients who were 
identified from other units, such as immunization and growth monitoring, were encouraged to visit the family 
planning unit if they needed contraceptive services. Clients who chose the ring during counseling were 
directed to the research assistant who completed the written informed consent process before providers 
could dispense the method. Clients were informed about study procedures, including the requirement to 
undergo pregnancy and HIV tests as part of inclusion and exclusion criteria, as well as the need for follow-up. 
Those clients who granted written informed consent were directed back to the provider for medical 
examination. Clients who qualified for the ring after satisfying the inclusion and exclusion criteria were then 
specifically counseled on the method and shown how to use it. Enrollment began at both sites in January 
2014 and was completed in July 2014. The last woman exited the study at both locations in January 2015. 
 
Providers were instructed to show enrolled participants how to insert and remove the ring, and to ensure 
that they left the facility with the ring properly inserted. In particular, providers were trained to insert the ring, 
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ask participants to remove it and reinsert themselves, and to confirm that they were not feeling it after 
reinsertion before leaving the facility. Clients who did not grant written informed consent and those who did 
not satisfy the inclusion and exclusion criteria after screening were offered other methods, even if they had 
initially chosen the ring. Clients who were given the ring were then interviewed by the research assistants 
upon exit. They were advised to return to the facility after three months (with the used ring) to obtain another 
one, or at any time in case of concerns regarding the use of the ring. During exit interviews, the research 
assistants obtained contact information to follow up with the clients in the event that they did not return to 
the study site. Given that the ring was being introduced in the context of a study, there were elaborate 
inclusion and exclusion criteria as outlined in the Appendix.  
DATA COLLECTION, MANAGEMENT, AND ANALYSIS 
The data collection process was guided by Case Report Forms (CRFs) that were designed to capture 
information on specific aspects of the research project. Each study participant completed an initial CRF to 
screen for eligibility to participate and to record information on medical history at baseline. Completion of 
additional CRFs was requested at various times; the forms recorded information on: 1) adverse events; 2) 
follow-up visits at months 1, 3 and 6; 3) missed visits; 4) pregnancy notification, pregnancy outcome, 
serious adverse events, early termination, and unscheduled visits. The additional CRFs were completed by 
the providers at the facilities as needed. 
  
Two data collectors per clinical site were provided with Galaxy Tablets (GTs)—personal digital assistants 
fitted with two ODK-based questionnaires (Baseline Social and Follow-Up). An on-site 
obstetrician/gynecologist, also referred to as the Principal Investigator (PI), supervised the activities of the 
providers and data collectors on a daily basis. 
 
The Principal Investigators provided continued mentorship on the principle of Good Clinical Practice (GCP) 
twice per month at each site to ensure that the study was progressing as designed and site researchers 
were following GCP guidelines. During any particular visit, study coordinators retrieved all recorded 
information from the software and immediately transferred the information electronically to the Population 
Council’s central data management unit in Nairobi, Kenya, at which time the data were converted into a 
more accessible software (such as Stata and Excel) and sent back to the Nigeria country office for local 
analysis. The processed data were also shared with the Population Council’s New York office and stored as 
backup and for use in the multicountry pooled analysis. 
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Results 
OVERALL STUDY METRICS 
A total of 97 women were screened for eligibility to 
participate. Of these 97, a total of 58 women were 
enrolled (Table 1). For every enrolled participant, a 
nonuser (a woman who did not choose to use the 
vaginal ring) was administered a short questionnaire 
on her method choice (after providing informed 
consent).  
Out of the 58 women who enrolled in the study, 47 
(81%) completed the study, meaning they completed 
the two-ring cycle (or 6 months). Only 5 women (8.6%) 
reported adverse events associated with the use of 
the PVR. There was no case of a serious adverse 
event (SAE) defined as the development of any life-
threatening medical condition or any condition that  
leads to a woman being admitted in a hospital while on  
the PVR, irrespective of the cause of the morbidity. 
 
DEMOGRAPHIC CHARACTERISTICS  
OF STUDY PARTICIPANTS  
Nearly all women in this study (58) were above the age 
of 20 years, with only 1 participant under 20 years of 
age (Table 2). Women between the ages of 20–29 and 
30–39 were fairly equally represented, 46.6% and 
51.7%, respectively (Table 2). In Nigeria, while the 
average unmet need for spacing is 12%, unmet need 
for women between the ages of 20–29 and 30–39 is 
31.8% and 22.6%, respectively (NDHS 2013). This 
observation indicates the potential of the PVR to 
address the disproportionately high unmet need in 
these age groups.  
Most of the participants were from urban (60.3%) and 
peri-urban (37.9%) areas, which conformed to the fact 
that both Wuse General Hospital in Abuja and UCH 
Ibadan are urban facilities. However, one participant 
from a rural area also chose to use the ring. Almost all 
the participants or users of the PVR completed 
secondary education or above (98.3%). About 80% of 
the participating women were gainfully employed, with 
up to 40% reporting employment in a professional 
occupation. In addition, all the women that participated 
in this study were married. 
 
  
TABLE 1  Rate of enrollment and participation 
in study 
Variable  (n) 
Number of women screened  97 
Number of women enrolled  58 
Number of women who completed the study 
(used two rings) 
 47 
Number of PVR nonusers  58 
Number of Adverse Events  5 
Number of Serious Adverse Events  0 
Data source: CRFs and Baseline survey. 
TABLE 2  Demographic characteristics of study 
participants 
Variable     (n) Percent 
Age   
   <20 
   20–29 
   30–39 
1 
27 
30 
1.7 
46.6 
51.7 
Place of residence 
    Urban 
    Peri-Urban 
    Rural 
 
35 
22 
1 
 
60.3 
37.9 
1.7 
Education 
   Primary 
   Secondary 
   College 
   University 
Occupation 
    Not Working 
    Nonprofessional 
    Professional 
Marital Status 
   Married  
Partner’s Occupation 
    Not Working 
    Nonprofessional 
    Professional 
 
1 
26 
14 
17 
 
12 
23 
23 
 
58 
 
33 
0 
34 
 
1.7 
44.8 
24.1 
29.3 
 
20.7 
39.7 
39.7 
 
100.0 
 
39.7 
0 
58.6 
Data source: Baseline survey.   
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REPRODUCTIVE AND FAMILY PLANNING HISTORY 
In this study, the majority of the participating women (64%) had less than 3 children at the time of 
enrollment, while 29% had between 3 and 5 children. (Table 3.) About 30% of pregnancies following the 
index birth in this study were unintended. The majority of the women in this study (72%) expressed that 
they would like to space their next pregnancy by at least 2 years. Wider availability of the PVR could 
provide an opportunity to mitigate the substantial unmet need for these women. 
An important observation that is 
particularly relevant for the ring is 
what appeared to be a high culture 
of spousal communication for family 
planning among study participants. 
About 97% of the users have 
discussed spacing their pregnancies 
with their spouses. Also, up to 62% 
of participating women are first-time 
users of family planning in general. 
In a society where decisions to use a 
method are predominantly informed 
by recommendations of friends and 
family members, to observe that 
more than half of the women are 
first-time users of family planning is 
very encouraging and bodes well for 
acceptability of the PVR in the 
general population. 
Out of 38% of users who have ever 
used a method, the most common 
method used was injectable 
contraceptives (10%). (Figure 1.) 
This is in line with the existing 
knowledge that injectables are the 
most used methods in Nigeria 
(NDHS 2003 and 2008). Closely 
following injectables are implants 
(9%), contraceptive pills and male 
condoms (both 7%), IUDs (3%), and 
emergency contraceptive pills (2%).  
  
TABLE 3  Reproductive history and family planning use 
Variable (n) Percent 
Children ever born   
   < 3 
   3–5 
   > 5 
37 
17 
4 
63.8 
29.3 
6.9 
Number of living children 
   < 3 
   3–5 
   > 5 
 
38 
16 
4 
 
65.5 
27.6 
6.9 
Pregnancy was intended 
   Yes 
   No 
Preferred spacing of next birth 
   1–2 years 
   3–5 years 
   6–8 years 
   > 8 years 
   No response 
Discussed pregnancy spacing with partner 
    Yes 
    No 
Prior use of a method 
    Ever used 
    Never used  
 
41 
17 
      
17 
25 
2 
2 
 12 
 
56 
2 
 
22 
36 
 
70.7 
29.3 
 
29.3 
43.1 
3.4 
3.4 
20.7 
 
96.6 
3.4 
 
37.9 
62.1 
Data source: Baseline survey.   
 
FIGURE 1 PREVIOUS METHOD USE AMONG USERS 
 
Data source: Baseline survey. 
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INITIAL IMPRESSIONS 
At the time of enrollment, prospective study participants were asked to provide their impressions of the PVR in 
respect to color, size, and texture. (Figures 2, 3, 4.) Most of the study population (91%) felt that the color was 
just fine. Only 7% felt that the ring was too bright. In respect to the ring’s size, up to 43% of participants at 
enrollment expressed that the ring was larger than ideal, although 55% felt that the ring’s size was just fine. 
The same also goes with impressions of the ring’s texture, as 52% felt that the texture was just fine while 35% 
thought it was too soft. However, these initial impressions appear to have changed during the duration of the 
study, particularly when participants were reinterviewed at follow-up visits.  
 
 
 
 
 
 
 
METHOD CHOICE (PVR USERS VS NONUSERS) 
Participating women expressed a wide range of opinions as to why they chose the vaginal ring over other 
available methods presented to them. Although no opinion was mutually exclusive, at least 35% of women 
indicated fewer side effects and 36% indicated the fact that the PVR is user-controlled as reasons why they 
chose the ring. (Figure 5.) The fact that the ring was given free of charge contributed to some of the reasons 
why 47% of the women opted for the ring, while another 16% were attracted by the fact that it’s short-acting. 
The majority of women in this study who did choose another method (47%) did so because they knew someone 
who had used their method of choice in the past. (Figure 6.) This is in conformity with our knowledge that 
women decide on family planning methods based on referrals from their significant others. Similarly, 17% of 
nonusers of the PVR continued using the methods they were familiar with, while 22% made their choice based 
on the perception that the method is easy to use. Lastly, about 10% of nonusers made their choice based on 
other nonspecific reasons. An important observation here is that while the majority of family planning users are 
using methods that were previously known to them or those that were recommended by friends and family 
members, it was possible to identify 97 women from the two facilities who expressed interest in using the 
vaginal ring despite seeing and learning about it for the first time. Methods chosen by nonusers included IUDs, 
implants, injectable contraceptives, and contraceptive pills. 
 
FIGURE 5 REASONS FOR PVR CHOICE
 
Data source: Baseline survey. 
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PERCEIVED QUALITY OF CARE 
Proper counseling and provision of balanced information are integral to the success of effective family planning 
services, thus the recruiters were trained to provide correct and adequate information to ensure that the choice 
of the PVR, or other method, was well-informed. This was considered a measure of the quality of care the 
women received at enrollment. Results showed that women have received adequate and balanced information 
and the quality of care they received was judged to be standard as far as PVR use is concerned. For example, all 
58 women confirmed that providers conveyed to them information on the minimum breastfeeding episodes per 
day required for the PVR to be effective as well as when to remove the ring, and have been encouraged to insert 
the rings by themselves before leaving the health facilities. (Table 4.) Nearly all the women (98%) were given the 
opportunity to ask questions and seek clarification, and were taught how to remove the rings. This provides 
insight into how family planning service providers may interact with prospective ring users when the method is 
eventually registered and introduced in Nigeria. 
 
ACCEPTABILITY 
As stated previously, acceptability in this study is measured by the continuation rate, user-related experiences 
and those of spouses, and opinions shared by providers and community stakeholders. The continuation rate at 
6 months was 81%. Other proxies of ring acceptability have been summarized in Table 5. In this analysis, the 
study compared the responses of participants who reported satisfaction using the ring with responses of 
participants who reported dissatisfaction in relation to some variables of interest. For example, all those who 
reported satisfaction and dissatisfaction found it very easy to insert the rings, with ease of removing and 
reinserting insignificantly diminishing among the dissatisfied compared with the satisfied (86%, 86%, and 93%, 
100%, respectively). 
  
FIGURE 6 REASONS FOR OTHER METHOD CHOICE 
 
Data source: Survey of nonusers. 
TABLE 4  Perceived quality of care 
Domain Item Response     (n)  Percent 
Counseling on 
the PVR method 
Provider conveyed minimum breastfeeding 
requirement 
Provider conveyed when to remove PVR 
Provider allowed respondent to ask questions 
Provider encouraged respondent to insert PVR 
Yes 
Yes 
Yes 
Yes 
 58 
58 
57 
58 
 100 
100 
98 
100 
Counseling on 
PVR use 
Provider showed how to insert PVR 
Provider showed how to remove PVR 
Yes 
Yes 
 58 
57 
 100 
98 
Data source: Baseline survey.  
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Furthermore, the proportions of satisfied women who responded “yes” to whether they felt the rings during sex, 
whether their partners felt the ring, or whether the ring affected the frequency of intercourse were slightly higher 
than those of their counterparts. However, there is a significant difference with regard to desired future use of 
the ring among the dissatisfied than the satisfied. While 92% of the satisfied would be interested in using the 
ring in the future, only 40% of the dissatisfied showed similar interest. Similarly, while 95% of the satisfied 
users’ partners/family would support the use of the ring and 100% of the satisfied users would recommend the 
ring, only 20% and 60% of the dissatisfied, respectively, would do the same. In the same vein, 71% of satisfied 
users would be willing to pay for the ring if it were available in the market while none of the dissatisfied users 
were willing to do so. In summary, while there is no significant difference in terms of ease of use of the ring 
between the satisfied participants and the dissatisfied, negative attitudes toward the ring seem to be mainly 
expressed among the dissatisfied. 
  
TABLE 5 Responses by satisfaction related to PVR use 
Domain Item Response Satisfied 
Not  
satisfied 
p-value Fisher’s 
Exact Test 
Ease of use Ease of inserting PVR 
Ease of removing PVR 
Ease of reinserting PVR 
Easy/Very easy 
Easy/Very easy 
Easy/Very easy 
100 
93 
100 
100 
86 
86 
1.00 
0.59 
0.06 
Side effects  Reported No 86 60 0.07 
Expulsion PVR fell out on its own No 97 100 1.00 
Sexual intercourse Felt PVR during sex 
Partner felt PVR during sex 
Change in frequency of sex 
Change in sexual pleasure 
No 
No 
No 
Increase 
79 
71 
84 
79 
60 
60 
79 
80 
0.23 
0.48 
0.37 
1.00 
Will use in future Interested Yes 92 
 
40 
 
0.00 
 
Partner/family would 
support use 
Reported Yes 95 
 
20 
 
0.00 
Will recommend Reported Yes 100 
 
60 
 
0.00 
 
Already recommended Reported Yes 86 
 
50 
 
0.02 
 
Willingness to pay Interested Yes 71 0 0.00 
Data source: Follow-up surveys. 
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WOMEN PARTICIPANTS  
 
TABLE 6 Responses by satisfaction related to PVR use 
Domain Comments 
Effect on breast milk                                       “Honestly, my breasts have never dry … my breast is floating (meaning flowing).” 
Perceived side effects 
 
“Methods such as implants have negative effects like weight gain. This ring does not. 
“It is just making me happy. It is just making me enjoy my marriage.” 
Effects on sex life “Yes, I am thinking … although we were informed by the providers that the ring is safe. But I am still 
afraid of it (the ring being expelled). But even after we have intercourse, the ring is still in place.”
  
Self-insertion “I feel somehow because I have not done something like that before … asked if whether I can put it 
by myself and I said no.” 
“I climb my chair, just put it … it just feel like I even more than sabi pass them (insert the rings) 
perfectly like say I be expert! Since I put it that day, the thing has not come out.”  
 
MALE PARTNERS  
 
TABLE 7 Responses by satisfaction related to PVR use 
Domain Comments 
Ease of use “Sometimes I ask her, this thing is not disturbing you? She say no, she is not feeling 
anything. So I say okay.” 
Sexual intercourse “The first time when you enter, you will know there is something there. When we take 
two or three days, it will become soft … I feel like I am using condom.” 
Continuation/discontinuation “No! Even before she delivered this baby I told her after this baby it is family planning. 
So even two years to come now, we are not thinking about having any other baby.” 
 
PROVIDERS  
 
TABLE 8 Responses by satisfaction related to PVR use 
Domain Before study After study 
Size of the ring Doubted if one size can fit all 
  
Perception changed as women of different sizes inserted 
and used the ring 
Ring to stay permanently Thought it would interfere with sex Perception changed with women who used it continuously 
for 6 months 
Women’s comfort Anxiety over discomfort if the ring is 
inserted 
This fear faded when women did not report any discomfort 
 
Note: Acceptability = continued (2 cycles), recommended, adhered, and will use in the future. 
Data source: In-depth interviews with husbands. 
Data source: Provider questionnaire (before and after). 
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COMMUNITY STAKEHOLDERS  
 
TABLE 9 Responses by satisfaction related to PVR use 
Domain Comments 
Questions and concerns “What position is it going to take if it enters your vagina? And can it really prevent the 
sperm from entering? The chemical … is it dissolving the sperm when it is releasing or 
what?”  
Fear of effect on babies “I think the chemical … will have effect on their baby.” 
Perception of women using the ring “Most women will like to buy it secretly; they can easily do it, without letting their 
husband know because their husband will prolong issues.” 
 
 
PARTNERS’ SUPPORT AND EXPERIENCE 
In general, the experiences of male partners 
were positive. Prior to the start of the study, 
stakeholders expressed concerns that 
women’s partners might dislike the ring since 
it is inserted vaginally, because it might 
interfere with sex. In this study, only 15% of 
partners reported changes in their sexual 
pleasure when their female partners were 
using the ring and a further 8% felt that the 
perceived changes in sexual pleasure were 
due to the ring’s presence in the vagina. 
(Figure 7.) Also, 23% reported feeling the ring 
during intercourse. However, psychological 
components to these perceptions must be 
ruled out. 
CONTINUATION 
One measure of acceptability is the extent to which women continue to use the product. Table 10, 
below, presents the results of an analysis that explored the relationship, if any, between key aspects of 
the use experience and continued use through two ring cycles. The hypothesis being tested is that a 
positive use experience will have a positive effect on continuation. 
In regards to the ease of use of the PVR, there was no difference among those who continued and those 
who terminated. Those who completed the study compared to those who terminated reported that it was 
easy and/or very easy to insert the ring. As a matter of fact, perception about the ease of removing the 
ring was better among terminators (100%) than among completers (89%). The general inference that 
can be made is that nearly all participating women believe that the ring is easy to insert and remove.   
 
  
 
FIGURE 7 PARTNERS’ REACTIONS ON PVR USE 
 
Data source: Follow-up surveys. 
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Data source: Focus group discussion. 
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One recurring concern among providers and 
clients alike was the possibility of the ring slipping 
out of the vagina and/or of partners feeling the 
ring during sexual intercourse; both of these 
concerns could affect adherence. Therefore, this 
study measured these experiences among those 
who completed the study compared with those 
who terminated. There was little difference among 
the terminators and completers in relation to 
whether the ring spontaneously fell out of place. 
For example, those who terminated never reported 
feeling the ring fall out of the vagina, and about 2% of those who completed the study reported this 
experience.  
However, the completers reported more favorable experience than the terminators regarding the 
experience of their spouses feeling the vaginal ring during sexual intercourse. Virtually all terminators 
reported that both they and their spouses felt the ring, while only 21% and 28% of the women and their 
spouses, respectively, who completed reported the same. The reported experiences were similar for 
whether the use of the ring affected the frequency of intercourse or sexual pleasure. Significant 
differences were noted in the domain of the PVR falling out on its own and during sexual intercourse. 
Only 9% of continuers felt the PVR fall out, whereas 50% of terminators felt the same. While 79% of 
continuers reported not feeling the PVR during sex, 85% reported no change or an increase in frequency 
of sex. Eighty-one percent of continuers reported no change or an increase in sexual pleasure, while 0% 
of terminators reported the same.  
As reported earlier, 11 out of the 58 enrolled women dropped out of the study without completing the 
two ring cycles. Not all women who discontinued the study returned to the facilities, and only three of 
the women who discontinued provided reasons for their actions. Of the three women who provided 
reasons, two expressed feeling uncomfortable with the ring and one stopped using the ring because she 
experienced symptoms of headache, dizziness, and fever and thus associated these symptoms with the 
use of the ring. (Figure 8.) In general, reasons provided for discontinuing the ring are nonspecific in 
nature and may not be connected to the use of the ring. 
  
TABLE 10  Responses by continuation related to PVR use 
Domain Item Response Completed 
(%) 
 Terminated 
(%) 
p-value Fisher’s 
Exact Test 
Ease of use Ease of inserting PVR 
Ease of removing PVR 
Ease of reinserting PVR 
Easy/Very easy 
Easy/Very easy 
Easy/Very easy 
100 
89 
96 
 100 
100 
100 
1.00 
0.57 
1.00 
Expulsion 
 
PVR fell out on its own 
Frequency of feeling the PVR 
No 
<1/week or never 
91 
79 
 50 
100 
1.00 
1.00 
Sexual 
intercourse 
Felt PVR during sex 
Partner felt PVR during sex 
Removal during sex 
Change in frequency of sex 
Change in sexual pleasure 
No 
No 
No 
No change or increase 
No change or increase 
79 
72 
95 
85 
81 
 0 
0 
50 
0 
0 
0.05 
0.09 
 0.11 
0.03 
0.04 
Data source: Baseline and follow-up surveys. 
 
FIGURE 8 REASONS FOR DISCONTINUING PVR 
 
Data source: Follow-up surveys. 
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ADVERSE AND SERIOUS ADVERSE EVENTS 
There were only five cases of adverse events (AEs) recorded during the study. As mentioned earlier, an AE is 
said to occur when a woman who is using the ring reports any sign or symptom irrespective of the actual cause 
of the complaint. In this study, three women reported transient irregular vaginal bleeding, a common side effect 
associated with all progesterone-based family planning methods such as the PVR. In all cases, the women were 
counseled and each continued with the ring to the end of the study. Another participant provided a nonspecific 
complaint for which she received counseling and completed the study without further complaint. One woman 
complained of fever and headache, which was treated with analgesics. This participant subsequently dropped 
out of the study despite reassurance from the providers that the side effect was not serious. In general, this 
study did not record any AE that can be said to be atypical of what is known of a progesterone-based 
contraceptive product. No serious adverse events were reported in this study. (Tables 11, 12.)  
 
TABLE 11  Adverse events 
Number Description Treatment 
3 Brief episode of bleeding Reassurance by provider 
1     Fever/headache   Provision of analgesics 
1 Nonspecific 
complaint   
Reassurance by provider 
Data source: Follow-up surveys. 
 
TABLE 12  Serious Adverse Events 
Number Description Treatment 
NIL  NIL  NIL 
Data source: Case report forms. 
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Discussion 
Almost half (47%) of the ring’s users were between the ages of 20 and 29—an age range when fertility is 
highest and family spacing need is greatest. The PVR, when introduced, will add to the available options 
for these mothers during the immediate postpartum period, and help meet the substantial unmet need 
(over 65%) during this period. It also appears that first-time users of family planning preferentially chose 
the PVR in this study, as over 62% of the participants were first-time users. Curiously, a study of 2,000 
women seeking family planning in UCH Ibadan (one of the study sites) revealed that the majority of the 
women made their choice of methods following advice from friends and family members (Konje et al. 
1998). Yet many first-time users who supposedly had received similar advice from friends and family 
members opted to use the PVR. This may suggest the extent to which the women found the ring 
appealing. Also, the fact that more than 36% of the users have three or more children and 50% wanted 
to delay their next pregnancies by at least two years indicates potential gaps that need to be filled. This 
is in line with findings from the recent NDHS (2013) where 67% of women do not want to have a baby 
within two years of their last birth. Therefore, should the PVR become available in the country, demand 
for the product would likely be high. 
This study revealed findings of interest that may influence future decisions in terms of registering the 
ring in Nigeria and its potential for adding value to the postpartum family planning landscape. The fact 
that it took only 97 women to be screened for eligibility in order to enroll the 58 required for the study 
(eligibility rate of 60%) is a testimony to the suitability of the PVR for many women. This is 
notwithstanding the strictest eligibility criteria applied for the study, some of which will not apply in 
routine clinical use. Another encouraging outcome is that up to 81% of the recruited women continued 
with the ring for up to six months. This is a big achievement for the ring given the knowledge that up to 
50% of women discontinue their current method of choice within six months of initiation. And of the 11 
users who terminated early, only 3 (27%) reported side effects as the reason for discontinuing the ring. 
This is comparable to a discontinuation rate of 29% due to side effects associated with injectable 
contraceptives in Nigeria (NDHS 2013).  
Although up to 47% of the participants indicated that one of the reasons why they chose the PVR was 
because it was given free, it seems the price alone could not have determined their choices. This study 
was conducted in public facilities where all other methods were equally free, the exception being that 
choosing methods other than the PVR would attract a service charge that is marginal and should be 
easily affordable given the urban locations of the study facilities and the relatively high socioeconomic 
status of the participants. For example, the Willingness To Pay (WTP) study conducted in the same 
facilities showed that all the women interviewed were willing to pay for the ring if it is available at N300 
(about US$2), and N300 is the median price for injectable contraceptives within the private sector in 
Nigeria. Thirty-six percent of women chose the ring because it is user-initiated and controlled. This is a 
very important attribute of the ring considering the general service environment where rural dwellers 
lack access to skilled providers and are unable to access highly effective methods especially during a 
period of greatest need. 
Among participants, the most common methods used previously were injectable contraceptives (10%) 
closely followed by implants (9%) and then contraceptive pills (7%), male condoms (7%), IUDs (3%), and 
emergency contraception (2%). Looking at the contraceptive need for the immediate postpartum period, 
for which the PVR is specifically designed, combined oral contraceptive pills are not an option until after 
6 months (WHO 2015). Similarly, access to injectables, IUDs, and implants requires family planning 
infrastructure with trained providers. The male condom is also not ideal for family planning purposes, 
given that it is coitally dependent and has a high failure rate in typical use. This suggests that when the 
PVR becomes available, it will expand choices for breastfeeding mothers. Because of the user-controlled 
aspect, it can be provided at both public and private clinics as well as in rural areas through patent 
medicine vendors (PMVs) and Community Health Extension Workers (CHEWs). 
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One concern that was frequently expressed was whether Nigerian women can easily insert and remove 
the ring by themselves, given the cultural sensitivity to touching one’s genitalia. This study showed that 
this fear is unfounded, as all participants found the ring either easy or very easy to insert. The ability to 
insert and remove the ring does not seem to be associated with continuation or termination, as all of 
those who terminated had no problem removing the ring.  
Almost all who discontinued the study reported that their partners felt the ring during sexual intercourse, 
while only 28% of those who completed the study had the same complaint. Contribution of psychological 
factors to this observation must be ruled out as this was a concern among all stakeholders and family 
planning service providers during the stakeholder dialogue and mapping prior to conducting the study. 
This complaint also persisted among the women themselves, with 21% and 100% of women feeling the 
ring at intercourse among the completers and early terminators, respectively. Because of this concern, 
50% of early terminators removed the ring during sexual intercourse as opposed to only 5% of the 
completers. While the influence of psychological factors is a strong possibility, future introductory effort 
must ensure that the women are taught how to push the ring high enough into the posterior fornix. As 
this is a new method utilizing vaginal route for administration, it will take some time for the population to 
overcome this concern. 
Another concern that was frequently voiced was the possibility of recurrent vaginal infection if the ring is 
left in the vagina for a long time. The evidence from this study supports the literature that states that 
ring usage does not increase vaginal infections. The only method-related complication reported was 
abnormal vaginal bleeding, which was mild in the three cases reported. All three cases were mainly 
spotting and the longest bleed lasted for only three days. This is a relatively common experience with 
most progestogenic agents, such as injectable contraceptives, implants, and the Levonorgestrel 
Intrauterine System (LNG IUS). As with other progesterone-based agents, the symptom is self-limiting 
and was effectively managed with proper counseling and reassurance. No serious adverse event was 
reported in this study. 
Further discussions and interviews with selected women users and their spouses, family planning 
providers who recruited and monitored the women, as well as community stakeholders provided deeper 
insight into their perspectives, which is relevant to our understanding of how the ring is introduced. For 
example, women have reported that the use of the PVR does not seem to affect the quality and quantity 
of their breast milk nor does it cause serious side effects. They are also very comfortable inserting the 
rings by themselves and their sexual lives were unaltered as a result of using the ring.  
  
ACCEPTABILITY 
Using the continuation rate as a measure of acceptability, the acceptability in this study is very high; 
more than 81% of participants continued the method for two rings cycles (six months). This observation 
is corroborated by other findings from the study. For example, although there was some hesitation on 
the part of providers during orientation training and on the part of users at enrollment, eventually 
women accepted inserting and removing the rings by themselves and continued to do this throughout 
the study period. With few exceptions, women and their partners generally were happy leaving the rings 
in their vaginas during intercourse. In one instance, a couple reported enhanced sexual pleasure when 
the ring was in place. Participants also reported unaltered breastfeeding volume and that their babies’ 
health remained sound throughout the length of time they used the ring.  
One remaining challenge is how to address some of the concerns of community stakeholders, because 
their misperceptions can influence how the ring is perceived when eventually introduced. For example, 
one stakeholder said that the chemical in the ring could have an effect on the babies. This is the kind of 
misperception that must be dispelled. 
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LESSONS LEARNED FOR FUTURE INTRODUCTION OF RINGS 
This study reveals a number of lessons that must be considered while the product is being registered, 
introduced, and distributed: 
 Clearly the introduction of the PVR will be a welcome development for the family planning service 
environment in Nigeria. The attitudes of the women and their spouses, and those of the providers 
toward the ring changed markedly by the end of the study. This is the first requirement of commodity 
introductory efforts. 
 About 62% of participants were first-time users of family planning and chose to use the PVR despite the 
availability of other established methods. In a society where family planning method choice is generally 
based on recommendations by significant others, this may indicate the huge potential of the PVR to 
add value to the postpartum family planning landscape in Nigeria. 
 It is good practice to remember that initial impressions and perceptions about a product being 
introduced may not necessarily be the same after actual use. At the end of the study, both the family 
planning providers and women participants expressed the opinion that the PVR is “one size fit all.” 
 The benefits of stakeholders’ engagement from the outset cannot be overemphasized. Early 
collaboration in this project with the FMoH and regulatory bodies such as NAFDAC is paving the way for 
a seamless registration process in the country and creating support from partners for the ring’s 
inclusion on the national Essential Medicines List. 
 Involvement of training institutions and professional bodies in the planning and implementation phase 
of the project can catalyze the uptake and consumption of new ideas by the target elements. In one of 
the study centers, which is a teaching institution for medical and nursing students, the PVR is already 
integrated in the curriculum for medical students. This will ensure that cohorts of future generations of 
doctors are exposed to the ring right from their schooling years. This is in addition to the number of 
obstetricians and gynecologists who were trained as local resource persons. This bodes well for future 
introductory efforts. 
 For any new commodity to be successfully introduced, the community must be sensitized well ahead of 
time to mitigate the possibility of misperceptions that could be difficult to eradicate once established. 
To this end, the Council is already partnering with a coalition of Civil Society Organizations (CSOs) to 
engage the community in a positive manner and to obtain feedback that would help situate the ring in 
a rights-based framework. 
 The interest that the national government has in the ring must be sustained, especially with the recent 
change of government at all levels. Luckily, the successful registration and introduction of the PVR is 
one of the priority areas of reproductive health interventions submitted to the new government by the 
Coalition of Civil Society Organizations in Nigeria. 
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Appendix 
 
APPENDIX A1: INCLUSION/EXCLUSION CRITERIA 
A. INCLUSION CRITERIA 
To participate in the study, a woman must meet all the inclusion criteria listed below at enrollment: 
1. Able to provide informed consent 
2. Age 18 to 35 years (inclusive) 
3. Has delivered a healthy singleton infant 6 to 9 weeks prior to study enrollment 
4. Has at least (1) living child and is fully/nearly fully breastfeeding the new infant  
5. Willing to continue breastfeeding infant a minimum of 4 times per day for at least 6 months 
6. Is in good health as confirmed by medical history, physical examination. (Includes vital signs and diagnosis/treatment of 
vaginal infection per the standard of care in Nigeria. Treatment of vaginal infection, if any, is required prior to enrollment.)  
7. Has or expects to have regular exposure to the risk of pregnancy 
8. Willing to choose the PVR as contraceptive method 
9. Willing and able to follow study procedures  
10. Expects to continue living in an area accessible to the study site for the duration of the study 
B. EXCLUSION CRITERIA 
Similarly, women with any of the following attributes were excluded from participating in the study: 
1. Is pregnant or suspected of being pregnant 
2. Breastfeeding less than fully/nearly fully 
3. Hypersensitivity to hormonal preparations or silicone rubber 
4. HIV positive or in a discordant relationship 
5. Presence of genital or urinary tract infection 
6. Dyspareunia 
7. History of Human Papillomavirus (HPV) 
8. History of bacterial infections such as Chlamydia and gonorrhea 
9. History of pelvic inflammatory disease (PID) or salpingitis since delivery 
10. History of chronic constipation 
11. Clinically relevant genital prolapse  
12. Has history of generalized urticaria 
13. Any chronic condition requiring continuous or regular use of medication or herbals prescribed by healers 
14. Has a history of thrombophlebitis or thromboembolism  
15. History of and/or current depression 
16. History of epilepsy or convulsive disorder  
17. Had an ectopic pregnancy 
18. Has vaginal bleeding not attributable to menses 
19. Known or suspected carcinoma of the breast 
20. Has had any other known or suspected neoplasia within last 5 years  
21. Not exposed to risk of pregnancy 
22. Use of chronic medications, Rifampicin, Griseofluvin, barbiturates, phenytoin, ketoconozole, butazoliden  
23. Confirmed hypertension (blood pressure–systolic more than 140 mmHg and/or diastolic of more than 90 mmHg 
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